GENE ONLINE|News &
Opinion
Blog

2025-11-29|

mTORC1 Signaling in ILC2s Identified as Key Link Between Nervous System and Allergic Lung Inflammation

by GOAI
Share To

A recent study has identified mTORC1 signaling in group 2 innate lymphoid cells (ILC2s) as a critical factor in the connection between the nervous system and immune responses during allergic lung inflammation. The research, published in *Nature Communications* by Wang, Hu, Chen, and their team, highlights the role of mTORC1 in mediating neuro-immune interactions that contribute to allergic reactions.

The findings reveal that mTORC1 activity within ILC2s plays a central role in regulating molecular pathways involved in allergic inflammation. ILC2s are known for their involvement in type 2 immune responses, which are commonly associated with allergies and asthma. This study provides evidence that mTORC1 signaling acts as a key mechanism through which these cells interact with neural signals to drive inflammatory processes. The research offers new insights into how the immune system communicates with the nervous system during allergic reactions and could have implications for understanding and managing conditions like asthma and other allergic diseases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top